Mucosal immunity and poliovirus vaccines: Impact on wild poliovirus infection and transmission

Vaccine

Volumn 29, Issue 46, 2011, Pages 8205-8214

  Okayasu, Hiromasa ^a   Sutter, Roland W ^a   Czerkinsky, Cecil ^b   Ogra, Pearay L ^c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b International Vaccine Institute   (South Korea)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Disease eradication; Mucosal immunity; Poliomyelitis; Poliovirus

Indexed keywords

AMYLASE; ANTIGEN; BCG VACCINE; CD155 ANTIGEN; CD27 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD69 ANTIGEN; CHOLERA TOXIN; CHOLERA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1; IRON; LACTOFERRIN; LYSOZYME; NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE; PATTERN RECOGNITION RECEPTOR; POLIOMYELITIS VACCINE; PROBIOTIC AGENT; RETINOIC ACID; ROTAVIRUS VACCINE; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VIRUS ANTIBODY; ZINC;

ADAPTIVE IMMUNITY; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM INFANTIS; BRONCHOEPITHELIUM ASSOCIATED LYMPHOID TISSUE; CELL PROLIFERATION; CHOLERA; COMMON VARIABLE IMMUNODEFICIENCY; DENDRITIC CELL; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; ENTEROVIRUS INFECTION; HEAVY METAL POISONING; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; INFECTION RISK; INNATE IMMUNITY; INTERFERON PRODUCTION; INTESTINE LYMPHATIC TISSUE; INTESTINE MUCOSA; LYMPHOID TISSUE; MACROPHAGE FUNCTION; MALNUTRITION; MATHEMATICAL MODEL; MEMORY T LYMPHOCYTE; MIXED INFECTION; MUCOSAL IMMUNITY; NASOPHARYNGEAL ASSOCIATED LYMPHOID TISSUE; NEWBORN CARE; NONHUMAN; PEYER PATCH; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; SEASONAL VARIATION; SEROCONVERSION; TROPICAL DISEASE; VACCINATION; VACCINE ASSOCIATED PARALYTIC POLIOMYELITIS; VACCINE FAILURE; VIRUS ENTRY; VIRUS EXCRETION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS STRAIN; VIRUS TRANSMISSION; VITAMIN SUPPLEMENTATION; WILD TYPE;

HUMANS; IMMUNITY, MUCOSAL; INDIA; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES;

EID: 80053948929     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.059     Document Type: Review

References (91)

1. Global Polio Eradication Initiative. Annual Report 2009. Available from: [accessed 06.06.11]. http://www.polioeradication.org/content/publications/AnnualReport2009_ENGChap2.pdf.
2. Global Polio Eradication Initiative. Polio this week. Available from: [accessed 07.07.11]. http://www.polioeradication.org/casecount.asp.
3. Kimpen J.L., Ogra P.L. Poliovirus vaccines. A continuing challenge. Pediatr Clin North Am 1990, 37:627-649.
4. Martín J., Minor P.D. Characterization of CHAT and Cox type 1 live-attenuated poliovirus vaccine strains. J Virol 2002, 76:5339-5349.
5. Minor P.D., Ferguson M., Evans D.M., Almond J.W., Icenogle J.P., et al. Antigenic structure of polioviruses of serotypes 1, 2 and 3. J Gen Virol 1986, 67:1283-1291.
6. Iwasaki A., Welker R., Mueller S., Linehan M., Nomoto A., Wimmer E. Immunofluorescence analysis of poliovirus receptor expression in Peyer's patches of humans, primates, and CD155 transgenic mice: implications for poliovirus infection. J Infect Dis 2002, 186:585-592. http://www.pubmed.gov/12195344.
7. Kimpen J.L., Ogra P.L. Poliovirus vaccines: a continuing challenge. Pediatr Clin North Am 1990, 37:627-649. http://www.pubmed.gov/2161507.
8. World Health Organization. WHO Vaccine-preventable diseases: monitoring system - 2009 global summary, Available from: ; 2009 December [accessed 06.06.11]. http://www.who.int/immunization/documents/WHO_IVB_2009/en/index.html.
9. Global poliovirus eradication initiative. Independent evaluation of major barriers to interrupting poliovirus transmission in India, Available from: ; 2009 October [accessed 06.06.11]. http://www.polioeradication.org/content/publications/AnnualReport2009_ENG.pdf.
10. Grassly N.C., Jafari H., Bahl S., Durrani S., Wenger J., Sutter R.W., et al. Asymptomatic wild-type poliovirus infection in India among children with previous oral poliovirus vaccination. J Infect Dis 2010, 201:1535-1543. http://www.pubmed.gov/20367459.
11. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005, 59:587-635. http://www.pubmed.gov/16153180.
12. Heyman D.I., Murphy K., Brigaud M., Aymard M., Tembon A., Maben G.K., et al. Oral poliovirus vaccine in tropical Africa; greater impact on incidence of paralytic disease than expected from coverage surveys and seroconversion rates. Bull World Health Organ 1987, 65:495-501.
13. Sutter R.W., Patriarca P.A., Brogan S., Malankar P.G., Pallansch M.A., Kew O.M., et al. Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among vaccinated children. Lancet 1991, 338:715-720.
14. Grassly N.C., Fraser C., Wenger J., Deshpande J.M., Sutter R.W., Heymann D.L., et al. New strategies for the elimination of polio from India. Science 2006, 314:1150-1153. http://www.pubmed.gov/17110580.
15. Patriarca A., Wright P., John T.J. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries. Rev Infect Dis 1991, 13:926-939.
16. Sutter R.W., John T.J., Jain H., Agarkhedkar S., Ramanan P.V., Verma H., et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010, 376:1682-1688.
17. Plotkin S.A., Vidor E. Poliovirus vaccine - inactivated. Vaccines 2008, 605-630. Elsevier, [chapter 25]. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
18. Sutter R.W., Patriarca P.A. Inactivated and live, attenuated poliovirus vaccines: mucosal immunity. Measles and poliomyelitis - vaccines and immunization 1993, 279-294. Springer, New York, NY, [chapter 22]. Edouard Kurstak (Ed.).
19. Zhaori G., Sun M., Ogra P.L. Characteristics of the immune response to poliovirus virion peptides after immunization with live or inactivated polio vaccines. J Infect Dis 1988, 158:160-165.
20. Faden H., Modlin J.F., Thoms M.L., McBean A.M., Ferdon M.B., Ogra P.L. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 1990, 162:1291-1297.
21. Onorato I.M., Modlin J.F., McBean A.M., Thoms M.L., Losonsky G.A., Bernier R.H. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis 1991, 163:1-6.
22. el-Sayed N., el-Gamal Y., Abbassy A.A., Seoud I., Salama M., Kandeel A., et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med 2008, 359:1655-1665.
23. World Health Organization. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Weekly Epidemiological Record 2010; No. 23, p. 213-28. Available from: ; 2010 June [accessed 06.06.11]. http://www.who.int/wer/2010/wer8523/en/index.html.
24. Jenkins H.E., Aylward R.B., Gasasira A., Donnelly C.A., Mwanza M., Corander J., et al. Effectiveness of immunization against paralytic poliomyelitis in Nigeria. N Engl J Med 2008, 359:1666-1674. PMID: 20573924.
25. World Health Organization Risk assessment: frequency and burden of VAPP, cVDPV and iVDPV. Report of the interim meeting of the Technical Consultative Group (TCG) on the Global Eradication of Poliomyelitis 2002.
26. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005, 59:587-635. Review. PMID: http://www.pubmed.gov/16153180.
27. Global Polio Eradication Initiative. Circulating vaccine-derived poliovirus1 (cVDPV) 2000-2011. Available from: [accessed 06.06.11]. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccinederivedpoliovirus.aspx.
28. Robertson S.E., Traverso H.P., Drucker J.A., Rovira E.Z., Fabre-Teste B., Sow A., et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1988, 1:897-899.
29. John T. Poliovirus vaccine and poliomyelitis control in India [abstract]. World Conference on Poliomyelitis and Measles 1992.
30. Alexander L.N., Seward J.F., Santibanez T.A., et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. J. Am. Med. Assoc. 2004, 292:1696-1701.
31. Dayan G.H., Thorley M., Yamamura Y., Rodríguez N., McLaughlin S., Torres L.M., et al. Serologic response to inactivated poliovirus vaccine; a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis 2007, 195:12-20.
32. Cuba IPV Study Collaborative Group Randomized, placebo-controlled trial of inactivated poliovirus in Cuba. N Engl J Med 2007, 356:1536-1544.
33. Kimpen J.L., Ogra P.L. Poliovirus vaccines. A continuing challenge. Pediatr Clin North Am 1990, 37:627-649. http://www.pubmed.gov/2161507.
34. Von Magnus H., Petersen I. Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Rev Infect Dis 1984, 6:S471-S474.
35. Dömök I. Experiences associated with the use of live poliovirus vaccine in Hungary, 1959-1982. Rev Infect Dis 1984, 6:S413-S418.
36. Lasch E.E., Abed Y., Marcus O., Gerichter C.B., Melnick J.L. Combined live and inactivated poliovirus vaccine to control poliomyelitis in a developing country - five years after. Dev Biol Stand 1986, 65:137-143.
37. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. Bull World Health Organ 1996, 74:253-268.
38. du Chatelet I.P., Merchant A.T., Fisher-Hoch S., Luby S.P., Plotkin S.A., Moatter T., et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine 2003, 21:1710-1718.
39. Modlin J.F., Halsey N.A., Thoms M.L., Meschievitz C.K., Patriarca P.A. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. J Infect Dis 1997, 175:S228-S234.
40. Herremans T.M., Reimerink J.H., Buisman A.M., Kimman T.G., Koopmans M.P. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 1999, 162:5011-5018.
41. Hovi T. Inactivated poliovirus vaccine and the final stages of poliovirus eradication. Vaccine 2001, 19:2268-2272.
42. Randomized, placebo-controlled trial of inactivated poliovirus in Cuba. N Engl J Med 2007, 356:1536-1544. Cuba IPV Study Collaborative Group.
43. Ghendon Y.U.Z., Sanakoyeva I.I. Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin's strains) in person after naturally and experimentally acquired immunity. Acta Virologica (Praha) 1961, 5:265-273.
44. Henry J.L., Jaikaran E.S., Davies J.R., Tomlinson A.J., Mason P.J., Barnes J.M., et al. A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg (Lond) 1966, 64:105-120.
45. Onorato I.M., Modlin J.F., McBean A.M., Thoms M.L., Losonsky G.A., Bernier R. Mucosal immunity induced by enhanced potency IPV and OPV. J Infect Dis 1991, 163:1-6.
46. Modlin J.F., Halsey N.A., Thoms M.L., Meschievitz C.K., Patriarca P.A. Humoral and mucosal immunity in infants induced by three sequential IPV-OPV immunization schedules. J Infect Dis 1997, 75:S228-S234. Baltimore Area Polio Vaccine Study Group.
47. Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327:291-295.
48. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007, 7:379.
49. Wilson CB, Kollmann TR. Induction of antigen-specific immunity in human neonates and infants. Nestle Nutr Workshop Ser Pediatr Program 2008;61:183-95.
50. Brandtzaeg P. Mucosal adaptive immunity: impact of exogenous stimuli and feeding. Presented at: Euroconference: Nutrition, Immune Functions and Health 2005.
51. MacDonald T.T., Spencer J. Ontogeny of gut associated lymphoid system in man. Acta Paediatr Suppl 1994, 83:3-5.
52. Ogra PL, Welliver RC Sr. Effects of early environment on mucosal immunologic homeostasis, subsequent immune responses, and disease outcome. In: Barker DJP, Bergmann RL, Ogra PL, editors. The window of opportunity: pre-pregnancy to 24 months of Age. Nestle Nutrition Workshop Ser Pediatr Program, vol. 6. Nestec Ltd, Vevey/S Karger AG, Basel, Switzerland; 2008. p. 145-81.
53. Bhaskaram P., Nair K.M., Hemalatha P., Murthy N., Nair P. Systemic and mucosal immune response to polio vaccination with additional dose in newborn period. J Trop Pediatr 1997, 43:232-234. PMID: 9283127.
54. Adenyi-Jones S.C., Faden H., Ferdon M.B., Kwong M.S., Ogra P.L. Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J Pediatr 1992, 120:686-689.
55. Klein N.P., Gans H.A., Sung P., Yasukawa L.L., Johnson J., Sarafanov A., et al. Preterm infants' T cell responses to inactivated poliovirus vaccine. J Infect Dis 2010, 201:214-222.
56. Vekemans J., Ota M.O., Wang E.C., Kidd M., Borysiewicz L.K., Whittle H., et al. T cell responses to vaccines in infants: defective IFNgamma production after oral polio vaccination. Clin Exp Immunol 2002, 127:495-498.
57. Mahon B.P., Katrak K., Nomoto A., Macadam A.J., Minor P.D., Mills K.H. Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor. J Exp Med 1995, 181:1285-1292.
58. Böttiger M. Polio immunity to killed vaccine: an 18-year follow up. Vaccine 1990, 8:443-445.
59. Krieg C., Maier R., Meyerhans A. Gut-homing (alpha(4)beta(7)(+)) Th1 memory responses after inactivated poliovirus immunization in poliovirus orally pre-immunized donors. J Gen Virol 2004, 85:1571-1579. PMID: 15166441.
60. Crotty S., Ahmed R. Immunological memory in humans. Semin Immunol 2004, 16:197-203. Review. PMID: 15130504.
61. Schittek B., Rajewsky K. Maintenance of B-cell memory by long-lived cells generated from proliferating precursors. Nature 1990, 346:749-751.
62. Serazin A.C., Shackelton L.A., Wilson C., Bhan M.K. Improving the performance of enteric vaccines in the developing world. Nat Immunol 2010, 11:769-773.
63. Scrimshaw N.S., SanGiovanni J.P. Synergism of nutrition, infection, and immunity: an overview. Am J Clin Nutr 1997, 66:464S-477S. PMID: 9250134.
64. Riepenhoff-Talty M., Uhnoo I., Chegas P., Ogra P.L. Effect of nutritional deprivation on mucosal viral infections. Immunol Invest 1989, 18:127-139. PMID: 2543624.
65. Adeiga A.A., Akinosho R.O., Onyewuche J. Evaluation of immune response in infants with different nutritional status: vaccinated against tuberculosis, measles and poliomyelitis. J Trop Pediatr 1994, 40:345-350. PMID: 7853439.
66. Bahl R., Bhandari N., Wahed M.A., Kumar G.T., Bhan M.K. Vitamin A supplementation of women postpartum and of their infants at immunization alters breast milk retinol and infant vitamin A status. J Nutr 2002, 132:3243-3248. WHO/CHD Immunization-Linked Vitamin A Group, PMID: 12421835.
67. Caidi H., Bennis F., Mouan N., El Aouad R. Evaluation of the response to vaccination against poliomyelitis and measles in malnourished children in Morocco. East Mediterr Health J 2004, 10:474-481.
68. Benyesh-Melnick M., Melnick J.L., Ramos-Alvarez M. Poliomyelitis infection rate among Mexican children fed attenuated poliovirus vaccines. Live Poliovirus Vaccines: Papers Presented and Discussions Held at the First International Conference on Live Poliovirus Vaccines. Special Publication No. 44 1959.
69. Myaux J.A., Unicomb L., Besser R.E., Modlin J.F., Uzma A., Islam A.M., et al. Effect of diarrhea on the humoral response to oral polio vaccination. Pediatr Infect Dis J 1996, 15:204-209.
70. Faden H., Duffy L. Effect of concurrent viral infection on systemic and local antibody responses to live attenuated and enhanced-potency inactivated poliovirus vaccines. Am J Dis Child 1992, 146:1320-1323. PMID: 1415071.
71. John T.J., Jayabal P. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am. J. Epidemiol 1972, 96:263-269.
72. Humphrey J.H. Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet 2009, 374:1032-1035.
73. Mullié C., Yazourh A., Thibault H., Odou M.F., Singer E., Kalach N., et al. Increased poliovirus-specific intestinal antibody response coincides with promotion of Bifidobacterium longum-infantis and Bifidobacterium breve in infants: a randomized, double-blind, placebo-controlled trial. Pediatr Res 2004, 56:791-795. http://www.pubmed.gov/15347767.
74. Yasui H., Ohwaki M. Enhancement of immune response in Peyer's patch cells cultured with Bifidobacterium breve. J Dairy Sci 1991, 74:1187-1195.
75. Ogra P.L. Mucosal immune system in neonatal period and early infancy. Pediatric Health 2010, 179:637-647.
76. Mestecky J., Russell M.W., Elson C.O. Perspectives on mucosal vaccines: is mucosal tolerance a barrier?. J Immunol 2007, 179:5633-5638.
77. Lepow M.L., Warren R.J., Gray N., Ingram V.G., Robbins F.C. Effect of Sabin type 1 poliomyelitis vaccine administered by mouth to newborn infants. N Engl J Med 1961, 264:1071-1078.
78. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 2007, 356:1536-1544. The Cuba, IPV Study Collaborative Group.
79. Dayan G.H., et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis 2007, 195:12-20.
80. Katz M., Plotkin S. Oral polio immunization of the newborn infant: a possible method for overcoming interference by ingested antibodies. J Pediatr 1968, 73:267-270.
81. Ahmed T., Svennerholm A.M., Al Tarique A., Sultana G.N., Qadri F. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine 2009, 27:1433-1439.
82. John T.J., Devarajan L.V., Luther L., Vijayarathnam P. Effect of breast-feeding on seroresponse of infants to oral poliovirus vaccination. Pediatrics 1976, 57:47-53.
83. John T.J., Jain H., Ravishankar K., et al. Monovalent type 1 oral poliovirus vaccine among infants in India: Report of two randomized double-blind controlled clinical trials. Vaccine 2011, 29:5793-5801.
84. Pickering L.K., Granoff D.M., Erickson J.R., Masor M.L., Cordle C.T., Schaller J.P., et al. Modulation of the immune system by human milk and infant formula containing nucleotides. Pediatrics 1998, 101:242-249.
85. Sartono E., Lisse I.M., Terveer E.M., van de Sande P.J.M., Whittle H., Fisker A.B., et al. Oral polio vaccine influences the immune response to BCG vaccination. A natural experiment. PLoS ONE 2010, 5:e10328.
86. Ota M.O., Vekemans J., Schlegel-Haueter S.E., Fielding K., Sanneh M., Kidd M., et al. Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002, 168:919-925. PMID: 11777990.
87. Rennels M.B. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. J Infect Dis 1996, 174:S107-S111.
88. Smith A.H., Lingas E.O., Rahman M. Contamination of drinking-water by arsenic in Bangladesh: a public health emergency. Bull World Health Organ 2000, 78:1093-1103.
89. Global poliovirus eradication initiative. Independent evaluation of major barriers to interrupting poliovirus transmission in India, Available from: ; 2009 October [accessed 06.06.11]. http://www.polioeradication.org/content/general/Polio_Evaluation_IND.pdf.
90. Yuki Y., Kiyono H. Mucosal vaccines: novel advances in technology and delivery. Expert Rev Vaccines 2009, 8:1083-1097.
91. Tonkin D.R., Jorquera P., Todd T., Beard C.W., Johnston R.E., Barro M. Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. Vaccine 2010, 28:3238-3246.